CD Biopharma Initiates Phase I Trial for CD-001 in Advanced Solid Tumors
Suzhou-based tumor immunotherapy specialist CD Biopharma has announced the first subject dosing of a Phase...
Kehua Bioengineering Gains NMPA Approval for Gene Polymorphism Detection Kits
China-based Shanghai Kehua Bioengineering Co., Ltd (SHE: 002022) has announced receiving marketing approvals from the...
Humanwell’s HWH340 Receives Clinical Approval for Prostate Cancer Treatment
Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) has announced that its Class 1 chemical drug...
Sichuan Biokin Re-submits IPO Application to Hong Kong Stock Exchange
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced that it has resubmitted its application...
Acotec’s Vericor-S2 Coronary Microcatheter Approved by NMPA
Acotec Scientific Holdings Ltd (HKG: 6669) has announced that its Vericor-S2 coronary microcatheter has received...
Lepu Biopharma Licenses Potential Best-in-Class ADC MRG007 to ArriVent
Lepu Biopharma Co., Ltd (HKG: 2157) has announced an exclusive licensing agreement with ArriVent BioPharma,...
Trump Signs Executive Order to Withdraw from WHO, Drawing Criticism
President Donald Trump has signed an executive order indicating the withdrawal of the United States...
Douyin Gains Approval to Establish Hospital in Beijing’s Zhongguancun
The Beijing Municipal Health Commission has approved Douyin, the Chinese short-form video hosting service owned...
NMPA Approves Synaptic Medical’s Cryoablation Device and Gene Methylation Detection Kit
China’s National Medical Products Administration (NMPA) has granted marketing approval for two new medical devices:...
Huadong Medicine’s MediBeacon TGFR System Receives FDA Marketing Clearance
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced receiving marketing clearance from the US...
MediLink’s YL201 Receives Breakthrough Therapy Designation for Nasopharyngeal Carcinoma
Suzhou-based biotech MediLink Therapeutics (Suzhou) Co., Ltd has announced receiving another breakthrough therapy designation (BTD)...
Jiangsu Lianhuan Completes Enrollment for Phase III Study of LH-1801 in Type 2 Diabetes
China-based Jiangsu Lianhuan Pharmaceutical Co., Ltd (SHA: 600513) has announced the completion of subject enrollment...
Arrowhead’s Plozasiran Accepted for FDA Review in Familial Chylomicronemia Syndrome
US-based Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has announced that the New Drug Application (NDA) for...
Keymed and InnoCare Announce Licensing Deal for CD20xCD3 Bispecific Antibody with Prolium
China-based Keymed Biosciences Inc. (HKG: 2162) and InnoCare Pharma (HKG: 9969, SHA: 688428) have jointly...
GSK’s Jemperli Approved for First-Line Endometrial Cancer Treatment in EU
UK-based GSK plc (NYSE: GSK, LON: GSK) has announced receiving approval from the European Commission...
Kelun-Biotech’s Tagitanlimab Receives NMPA Clearance for Nasopharyngeal Carcinoma
China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced receiving another clearance from the...
Junshi Biosciences Licenses Toripalimab to LEO Pharma for EU and UK Markets
China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced a licensing agreement...
CARsgen Therapeutics Initiates Trial for Universal CAR-T Therapy KJ-C2320 in AML
China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced the first subject dosing in an...
Danaher Partners with Huashan Hospital to Develop Alzheimer’s Diagnostic Solutions
US-based science and tech services giant Danaher Corporation (NYSE: DHR) has announced a partnership between...
Chongqing Genrix’s Xeligekimab Approved for Ankylosing Spondylitis by NMPA
China-based Chongqing Genrix Bio Pharmaceutical Co., Ltd (SHA: 688443) has announced receiving approval from the...